BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Illimis Therapeutics Raises Series B to Advance GAIA Platform for Alzheimer’s and Immune Disorders

The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' visi...

July 15, 2025 | News

Ascletis Completes Dosing in U.S. Trial of ASC47 and Semaglutide for Obesity

The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day ...

July 15, 2025 | News

No More Whisper Networks: FDA Puts Its Rejection Reasons in Writing — Publicly

FDA Embraces Radical Transparency by Publishing Complete Response Letters For Immediate Release: July 10, 2025 &nb...

July 11, 2025 | News

FDA Finalises Guidance on Drug Development for Early Lyme Disease: A Strategic Signal for Industry Innovation

This finalised guidance serves as a blueprint for biopharmaceutical developers aiming to address early manifestations of Lyme disease—particularly ea...

July 11, 2025 | Analysis | By BioPharma APAC Desk

Unlocking Solubility as Lubrizol's Excipients Power the Next Generation of Drug Delivery

With up to 90% of new chemical entities suffering from poor water solubility, pharmaceutical innovators are under pressure to reformulate for eff...

July 09, 2025 | Interview

FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut

The FDA’s recent decision to cut its workforce by 20 percent has raised concerns across the biopharma industry, with experts warning of inevitable de...

July 09, 2025 | Opinion | By Lindsay Mateo, Chief Commercial Officer at Weave Bio

Sirtex Secures FDA Approval for SIR-Spheres® Y-90 in Treating Unresectable Hepatocellular Carcinoma

Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (F...

July 08, 2025 | News

ImmunityBio Secures First International Approval for ANKTIVA® in the UK for Bladder Cancer Treatment

ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, he...

July 08, 2025 | News

Smarter Together: How Molecule GEN Transforms Cross-Functional Drug Discovery

This cloud-native, SaaS-based platform breaks down traditional barriers in drug discovery by uniting all disciplines—biology, chemistry, and computat...

July 07, 2025 | Opinion | By Saurabh Singal | CEO-Founder, Molecule AI

Biosynth Expands GMP Bioconjugation Facility in Berlin to Advance Next-Generation Therapeutics

Biosynth, a leading developer and supplier of critical raw materials and services for life sciences and diagnostics, is pleased to announce the openi...

July 07, 2025 | News

Dizal Secures FDA Approval for ZEGFROVY, the First Targeted Oral Therapy for EGFR Exon20ins NSCLC

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins Approval follows the U....

July 03, 2025 | News

Switzerland’s RDP Pharma and Singapore’s A*STAR EDDC Join Forces to Develop Precision Autoimmune Therapies

RDP Pharma AG, a Swiss biotechnology company focused on next-generation protein degradation therapeutics, and the Experimental Drug Development...

July 02, 2025 | News

GenNext and Thermo Fisher Partner to Deliver End-to-End Protein Footprinting Workflow for Biologic Drug Development

GenNext® Technologies, Inc., a pioneer in protein footprinting, is collaborating with Thermo Fisher Scientific, the world leader in serving science, to...

July 02, 2025 | News

Southeast Asia Poised to Lead AI-Driven Healthcare Transformation Amid Rising Cross-Border Collaboration

The Southeast Asia (SEA) region’s role in healthcare innovation, long bolstered by Singapore’s commitment to serve as a g...

July 01, 2025 | Opinion | By Chu Canh Chieu, FPT Software Managing Director of Global Healthcare Center, FPT Corporation

Stay Connected